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1.0. Docking of initial ligand SJ02  
 
The initial ligand design (SJ02) was based on previous work but this proved difficult to 
synthesise efficiently. Therefore, the design focused on simpler glycine-dervied Ugi products 
SJ047 and SJ055 which have the amine available as a point of attachment for linking to the 
support. These were predicted to bind well to the target, and were easy to synthesise in solution. 
 
Figure S1.   Solid phase ligand SJ02 coupled to 1,4-butanediol diglycidyl ether: 15Å spacer 
arm. 
 
Figure S2. Docking of ligand SJ02 showing the binding interactions between the ligand and 
the ferritin target site. (a) The magnified binding sites of ferritin (3 subunits). The three residues 
of the hydrophobic region can be observed (Gln85, Thr84 and Leu83) on the surface. b) Highest 
scoring docking result of ligand SJ02 (orange) interacting with the most accessible 
hydrophobic binding pocket.Hydrogen bonds are formed between ferritin residues and the 
ligand SJ02.  
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2.0. Characterisation of Boc-SJ047  
 
Boc-SJ047, tert-butyl (2-((2-(cyclohexylamino)-2-oxo-1-phenylethyl)(furan-2-
ylmethyl)amino)-2-oxoethyl)carbamate  
White solid. Yield 95%. 1H NMR (400 MHz, CDCl3) δ 7.31-7.28 (m, 5H, Ha), 7.24 (d,1H, 
J=1.1 Hz, Hb*), 6.15 (s, 1H,Hb1), 5.90 (s,1H, Hc), 5.73 (s,1H,Hb2), 5.49 (s, 1H, Hd), 4.52 
(d,1H,J=17.8 Hz, He), 4.50 (d,1H,J=17.8 Hz, He), 4.21 (s, 2H, Hf), 3.81 (tq, 1H,J=11.2, 3.8 Hz, 
Hg), 1.96-1.86 (m, 2H, Hh), 1.73-1.58 (m, 3H, Hh) 1.47 (s, 9H, Hi), 1.42-1.28 (m, 2H, Hh), 1.19-
1.05 (m, 3H, Hh). 
13C NMR (400 MHz, CDCl3) 155.7, 142.1, 134.4, 129.6, 128.7, 128.6, 110.5, 
108.0, 79.6, 64.1, 63.1, 48.7, 42.9, 42.6, 32.8, 28.4, 25. 5, 24.8, 24.7. LRMS (ES+) 470 (M+H). 
HRMS (ES+) calculated for "C26H36O5N3" 470.2649 (M+H), found 470.2632. 
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2.1. Characterisation of deprotected ligand SJ047 
Before immobilisation, ligand SJ047 was deprotected and fully characterised.  
 
 
Deprotected SJ047, 2-amino-N-(2-(cyclohexylamino)-2-oxo-1-phenylethyl)-N-(furan-2-
ylmethyl)acetamide  
White solid. Yield 64%. 1H NMR (400 MHz, CDCl3) δ 7.42-7.29 (m, 5H, Ha), 7.22 (s,1H, Hb*), 
6.14 (s, 1H,Hb1), 5.9 (s,1H, Hc), 5.74 (s,1H,Hb2), 5.63 (s, 1H, Hi), 4.5 (s, 2H, Hf), 3.82-3.78 (m, 
1H, Hg), 3.68 (s,2H, He), 2.13 (s, 2H, Hd), 1.90-1.06 (m, 10H, Hh). 
13C NMR (400 MHz, CDCl3) 
168.5, 161.4, 141.7, 134.9, 129.6, 129.3, 128.7, 128.6, 126.5, 110.5, 108.6, 62.7, 48.6, 43.9, 
42.2, 32.8, 25.5, 24.8, 24.7. LRMS (ES+) 370 (M+H). HRMS (ES+) calculated for 
"C21H28O3N3" 370.2125 (M+H), found 370.211 
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3.0. Characterisation of ligand Boc-SJ055 
 
Boc-SJ055, tert-butyl(2-((2-(cyclohexylamino)-2-oxo-1-(pyridin-2-yl)ethyl)(furan-2 
ylmethyl)amino)-2-oxoethyl)carbamate.  
Yellow oil. Yield 71%. 1H NMR (400 MHz, CDCl3) δ 8.52 (s, 1H, Ha*), 7.64-7.60 (m, 1H, Ha), 
7.52 (s, 1H, Hd), 7.30-7.24 (m, 2H, Ha), 7.21-7.19 (m, 1H, Hb*), 6.19 (s, 1H,Hb1), 6.0 (s,1H, 
Hc), 5.77 (s,1H,Hb2), 5.48 (s, 1H, Hd*), 4.71 (d, J=16.9 Hz, 1H, He ), 4.66 (d, J=16.9 Hz, 1H, 
He )4.26 (s, 2H, Hf), 3.88-3.79 (m, 1H, Hg), 1.95-1.85 (m, 2H, Hh), 1.73-1.57 (m, 3H, Hh), 1.46 
(s, 9H, Hi), 1.44-1.33 (m, 2H, Hh), 1.30-1.13 (m, 3H, Hh). 
1H NMR 
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3.1. Characterisation of deprotected ligand SJ055  
 
Deprotected SJ055, 2-amino-N-(2-(cyclohexylamino)-2-oxo-1-(pyridin-2-yl)ethyl)-N-
(furan-2-ylmethyl)acetamide 
Yellow solid. Yield 62%. 1H NMR (400 MHz, CDCl3) δ 8.58 (d, 1H, J=4.19, Ha2) , 7.72 (td, 
1H, J=7.7, 1.7 Hz, Ha), 7.6-7.5 (m,1H, Ha1), 7.29-7.28 (m,1H,Ha*), 7.19 (s, 1H, Hb*), 6.3 (dd, 
J=3.2, 1.7 Hz, 1H, Hb1), 6.24 (d, J=3.2 Hz, 1H, Hb2), 6.18 (s, 1H, Hd*), 5.86 (s,1H, Hc), 5.20 (d, 
J=15.6 Hz, 1H, Hf), 4.52 (d, J=16.8 Hz, 1H, He), 4.03 (d, J=16.8 Hz, 1H, He), 3.82 (d, J=15.6 
Hz, 1H, Hf), 3.87-3.82 (m, 1H, Hg), 1.87 (s, 2H, Hd), 1.72-1.11 (m, 10H, Hh). 
13C NMR (400 
MHz, CDCl3) 166.5, 165.5, 154.9, 150.2, 148.8, 148.4, 143.0, 137.1, 123.7, 123.5, 110.5, 
110.0, 64.5, 45.6, 40.4, 36.2, 32.8, 32.7, 25.6, 25.1, 24.6. LRMS (ES+) 371 (M+H). HRMS 
(ES+) calculated for "C20H27O3N4" 371.2078 (M+H), found 371.2068. 
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4.0. Fluorescent Ligand SJ056  
 
Orange solid. Yield 60%. 1H NMR (400 MHz, CDCl3) δ 7.42-7.28 (m, 9H, Ha), 7.23 (s, 1H, 
Hb*), 6.14 (s, 1H,Hb1), 5.98 (s,1H, Hc), 5.64 (s,2H,Hb2), 5.64 (s, 2H, Hi), 4.5 (s, 2H, Hf), 3.83-
3.79 (m, 1H, Hg), 3.69 (s,2H, He), 1.90-1.07 (m, 10H, Hh). LRMS (ES+) 494 (M+H). HRMS 
(ES+) calculated for "C31H32O3N3" 494.2438 (M+H), found 494.2424. 
1H NMR 
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5.0. Control Experiments 
 
First, the unmodified Sepharose CL-4B column was tested with the crude mixture (Figure S3a). 
It was observed that the recombinant antigen was predominantly in the flow-through and wash 
fractions. This suggested that even in a salt binding buffer concentration of 20 mM PIPES and 
1.6 M ammonium sulphate, the recombinant antigen was not being bound non-specifically to 
the beads and eluted in the flow-through fractions. In addition, PEGDE 500 was coupled to the 
Sepharose CL-4B beads and cis-diol functionalised. The epoxide groups of the coupled PEG 
spacer were converted into cis-diol because the epoxides would interact with the free primary 
amine groups on the recombinant antigen in a ring-opening process. A similar behaviour was 
found for the PEG cis-diol functionalised packed column, where, ~73% of the HA (New 
Caledonia)–ferritin was observed in the flow through and binding fractions (Figure S3b). 
However, some of the HEK HCP was seen in elution, presumably due to the high salt 
concentrations encouraging hydrophobic interactions between the PEG and the recombinant 
antigen along with HEK host cell protein (HCP) impurities. In the molecular modelling, it was 
suggested that the PEG spacer arm binds to the recombinant antigen; however, in this instance 
it could be due to the high salt increasing the probability of binding. The PEG cis-diol 
functionalised packed column, eluted to a purity of ~76% and yield of ~27%. Therefore, these 
results suggested that at 1.6 M ammonium sulphate concentration the PEG spacer arm binds 
and elutes HA (New Caledonia)-ferritin and the HCP impurities.  
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Figure S3. Control experiments of Sepharose beads without immobilised ligands using crude 
supernatant. Colloidal blue SDS-page of: (a) Clarified HEK expressed HA (New Caledonia)-
ferritin supernatant (0.1 mg/mL) loaded onto the ~1 mL unmodified Sepharose CL-4B packed 
column and ran on the ÄKTA avant. (b) Clarified HEK expressed HA (New Caledonia)-ferritin 
supernatant (0.1 mg/mL) loaded onto ~1 mL cis-diol PEG coupled Sepharose packed column 
and ran on the ÄKTA avant.Using densitometry analysis (ImageJ), calculated yield and purity 
of lane E2 was ~27% and ~76%, respectively. Legend for SDS-PAGE above, M: Marker (Pre-
stained 10 kDa ladder), P: Purified HA (New Caledonia)-Ferritin (5 µg), S: Crude HEK HA 
(NC)-ferritin supernatant (100 µg), FT: Column wash (20 mM PIPES, 1.6 M (NH4)2SO4), W: 
Column wash (20 mM PIPES, 1.6 M (NH4)2SO4), EX: Gradient elution fraction to 20 mM 
PIPES, R: Regeneration fraction. 
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6.0. Human embryonic kidney host cell protein (HCP) impurities 
 
Samples were sent for MALDI mass spectrometry analysis of the HEK supernatant proteins 
(Figure S4). It was evident that all the HCP impurities were derived from the human embryonic 
kidney cell line and indicating that the supernatant is free from other contaminants (Table 1). 
The HCP impurities in elution fractions need to be minimised using the functionalised resins 
to obtain purified recombinant antigens. 
 
Figure S4. SDS-PAGE of HCP impurities in the HEK supernatantof purified and spiked HA 
(New Caledonia)-Ferritin samples. 
 
Table 1. SDS-PAGE protein bands (1-10) analysed using MALDI mass spectrometry. 
Band HEK cell supernatant impurities analysed by MALDI  
1 HSP70-2 [Homo sapiens]: Heat shock protein aids with protein folding.  
2 Glucose-6-phosphate isomerase isoform 4 [Homo sapiens]: glycolytic 
enzyme  
3 - 
4 L-lactate dehydrogenase B chain LDBH [Homo sapiens]: catalysis 
enzyme 
5 HSP70-2 [Homo sapiens] 
6 Nucleobindin 1, isoform CRA b [Homo sapiens]: calcium binding 
protein 
7 Chain A, Crystal structure of human enolase 1: glycolytic enzyme 
8 HSP70-2 [Homo sapiens] 
9 Neuroleukin [Homo sapiens]: neuronal growth factor, Glucose-6-
phosphate isomerase isoform 4 [Homo sapiens] 
 
M P 1X L 5X 
Legend: 
M: Marker (Pre-stained 10 kDa ladder) 
P: Purified HA (New Caledonia)-Ferritin (5 
µg) 
1X: 1X supernatant of HEK culture 
5X 5X supernatant of HEK culture 
L: Load ~100µg HA (New Caledonia)-ferritin 
spiked into HEK supernatant 
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7.0. Capacity studies for HA (NC)-Ferritin from HEK cell supernatants 
 
The Coomasie blue stained SDS-page below shows the capacity of binding the antigen for the 
immobilised ligands. The HA(NC)-ferritin load and the ammonium sulphate content in the 
wash buffer was increased as indicated in the figures below.  
 
Figure S5. Capacity of SJ047- immobilised resins in increasing concentrations of HA-ferritin 
load (0.1 – 1.7 mg/mL).(a)-(c) In 20 mM PIPES and 1.08M ammonium sulphate wash buffer, 
breakthrough of the antigen was observed in the flow through and wash fractions across all 
loaded concentrations.  (d) The wash buffer was changed to 1.2 M ammonium sulphate, 
breakthrough was till observed in the wash and flow through fractions. However, comparing 
the salt content of 1.08 M to 1.2 M with the same load of 0.1 mg/mL, more protein was being 
observed in the elution fractions for 1.2 M concentration. Legend for SDS-PAGE above, M: 
Marker (Pre-stained 10 kDa ladder), P: Purified HA (New Caledonia)-Ferritin (5 µg), S: Crude 
HEK HA (NC)-ferritin supernatant load (X mg/mL), FT: Column wash (20 mM PIPES, X M 
(NH4)2SO4), W: Column wash (20 mM PIPES, X M (NH4)2SO4), EX: Gradient elution fraction 
to 20 mM PIPES, R: Regeneration fraction. 
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Figure S6. Capacity of SJ047- immobilised resins in increasing the ammonium sulphate 
concentration to 1.6M.In 20 mM PIPES and 1.6M ammonium sulphate wash buffer, 
breakthrough was not observed for the (a) 0.05 mg/mL to (b) 0.1 mg/mL. (c) However, as the 
load increased to 0.25 mg/mL and the column became saturated, breakthrough was seen in the 
flow through and wash fractions. Legend for SDS-PAGE above, M: Marker (Pre-stained 10 
kDa ladder), P: Purified HA (New Caledonia)-Ferritin (5 µg), S: Crude HEK HA (NC)-ferritin 
supernatant load (X mg/mL), FT: Column wash (20 mM PIPES, X M (NH4)2SO4), W: Column 
wash (20 mM PIPES, X M (NH4)2SO4), EX: Gradient elution fraction to 20 mM PIPES, R: 
Regeneration fraction. 
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Figure S7. Capacity of SJ055-immobilised resins in increasing the ammonium sulphate 
concentration from 1.2M to 1.6M (a) In 20 mM PIPES and 1.2M ammonium sulphate wash 
buffer, breakthrough was observed for the 0.1 mg/mL load. (b) However, as the salt 
concentration increased to 1.6M and load remained the same to 0.1mg/mL, the salting effect 
adsorbed the antigen to the hydrophobic ligand and breakthrough was not observed in the wash 
fractions. (c) However, as the load increased to 0.25 mg/mL and the column became saturated, 
breakthrough was seen in the flow through and wash fractions. Legend for SDS-PAGE above, 
M: Marker (Pre-stained 10 kDa ladder), P: Purified HA (New Caledonia)-Ferritin (5 µg), S: 
Crude HEK HA (NC)-ferritin supernatant load (X mg/mL), FT: Column wash (20 mM PIPES, 
X M (NH4)2SO4), W: Column wash (20 mM PIPES, X M (NH4)2SO4), EX: Gradient elution 
fraction to 20 mM PIPES, R: Regeneration fraction. 
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8.0. Optical Density measurement at 350 nm 
 
1 mL samples of 0.1 mg/mL of HA (New Caledonia)- ferritin samples in 20 mM PIPES, 1.6 
M ammonium sulphate were agitated and measured to check for recombinant antigen 
aggregation.  
Table 2. Absorbance measurement (at λ=350 nm and 360 nm) of 0.1 mg/mL HA (New 
Caledonia)- ferritin agitated for 5 hours in 20 mM PIPES and 1.6M Ammonium Sulphate 
Time (h) Absorbance at 350 nm Absorbance at 360 nm 
1 0.0006 0 
2 0.0009 0.0008 
3 0 0 
4 0 0 
5 0 0 
 
 
 
